 U.S.-listed shares of Valneva VALN, -13.47 soared 81.9 in premarket trading on Tuesday, the day after Pfizer Inc. PFE, -2.00 announced a 95 million equity investment in Valneva as part of a previously established agreement aimed at developing a Lyme disease vaccine. The investment is expected to support the Phase 3 clinical trials for the Lyme disease vaccine candidate, which are set to begin in the third quarter of this year. 